AI-generated research brief — verify at source
Early Top-Down Anti-TNF Therapy Cuts Crohn’s Surgery Risk Fivefold Over Five Years
In a five-year follow-up of a randomised controlled trial, patients with newly diagnosed Crohn’s disease who received top-down treatment with infliximab plus an immunomodulator faced roughly five times the surgical risk if they had instead been managed with a conventional step-up approach (aHR 5.23, 95% CI 1.99–13.76, p=0.0008). The finding is consistent across multiple secondary outcomes and raises the possibility that initiating biological therapy at diagnosis may alter the underlying disease course rather than simply controlling symptoms.
What Was Studied
This study examined whether early initiation of anti-TNF biological therapy from the point of Crohn’s disease diagnosis produces durable long-term benefits compared with the conventional practice of escalating treatment only after simpler therapies fail. The primary outcome of interest was the need for Crohn’s disease-related abdominal surgery over up to five years of follow-up, a hard endpoint reflecting serious disease progression.
How It Was Studied
This analysis reports the long-term follow-up of PROFILE, a multicentre, open-label, randomised controlled trial conducted across 40 hospitals in the United Kingdom. Adults aged 16 to 80 years with a new diagnosis of Crohn’s disease were enrolled and randomly assigned to either a top-down strategy (infliximab combined with an immunomodulator) or a protocolised conventional step-up treatment for the first 48 weeks. A total of 386 participants formed the intention-to-treat population, of whom 358 (93%) had post-week 48 records available. After the initial 48-week protocol period, participants reverted to local standards of care, and outcome data were extracted for up to five years from randomisation, with a median follow-up of approximately 1,809 days. Time-to-event analyses used Kaplan-Meier methods and Cox proportional hazards modelling.
What Was Observed
- Abdominal surgery was substantially less common with top-down treatment. Only six surgeries occurred in six patients in the top-down group, compared with 28 surgeries in 26 patients in the step-up group. Patients originally assigned to step-up treatment reached surgery approximately five times sooner and more frequently than those who received early biological therapy (aHR 5.23, 95% CI 1.99–13.76, p=0.0008).
- Hospital admissions were approximately twice as likely in the step-up group. Crohn’s-related admissions occurred in 41 of 193 step-up patients (21%) versus 22 of 193 top-down patients (11%), with time to first admission being significantly shorter in the step-up arm (aHR 2.01, 95% CI 1.18–3.41, p=0.017).
- Structural disease complications progressed more often under step-up care. Progression to more severe disease phenotypes (B2 or B3 complications, such as stricturing or penetrating disease) was recorded in 32 of 192 step-up patients (17%) versus 13 of 193 top-down patients (7%), with step-up patients reaching that endpoint roughly 2.5 times faster (aHR 2.46, 95% CI 1.25–4.86, p=0.010).
- Safety outcomes were broadly comparable between groups. Serious infections occurred in 6% of step-up and 7% of top-down patients, and malignancies were rare in both groups (3% vs 2%), with no statistically meaningful differences identified between the two treatment strategies.
Why This Matters
Crohn’s disease has historically been managed through progressive escalation of therapy, reserving biological agents for patients who fail earlier treatments. This five-year dataset from a randomised trial demonstrates that deferring biological therapy is associated with substantially worse surgical and structural outcomes, suggesting that the timing of treatment initiation — not merely the eventual drugs used — may influence disease trajectory. The authors characterise this pattern as suggestive of a disease-modifying effect, a concept with meaningful implications for how newly diagnosed patients are counselled and managed from the outset.
How to Read This Result
Although the direction and magnitude of benefit consistently favour early top-down therapy across all major endpoints, interpretation should remain cautious: the open-label design precluded blinding, and the reversion to uncontrolled local standards of care after week 48 introduces meaningful variability in subsequent treatment exposure that makes it difficult to attribute all long-term differences solely to the original treatment allocation.
Limitations
The trial was open-label, meaning neither participants nor clinicians were masked to treatment assignment, which may have influenced clinical decision-making during follow-up. Participants lacking post-week 48 records were censored at that visit rather than followed further, potentially underrepresenting outcomes in a small subset. Crucially, the structured treatment protocol ended at 48 weeks, after which care reverted to local clinical practice — introducing substantial between-patient and between-centre variability in subsequent therapy that complicates attribution of long-term differences to the initial randomised strategy alone. Follow-up data were available for 93% of participants, leaving a residual, if modest, risk of attrition bias.